Pandemic vaccination did not increase risk of fetal death

With the rapid progression of molecular biology and genetics, and the subsequent emergence of many new targets, emerging targets & therapeutics provides new opportunities for the prevention and treatment of several major disease systems. The 4th Cancer Targets & Therapeutics Conference, taking place on February 25-26, 2013 in Las Vegas, NV will continue to be a premier event for translational researchers, preclinical scientists and managers, and those carrying out early phase clinical trials, working to identify and exploit advances in the field in order to deliver products with a meaningful clinical impact. Both cutting-edge researchers and those who guide its commercial development will be on-hand to share their knowledge and insights as to how therapeutic cancer targets are identified, and how this research translates into meaningful therapeutics that benefit patients living with cancer.

Attendees will learn about:

• Important progress in key aspects of antibody, vaccine, and cell-based therapies being developed and evaluated in clinical trials for the immunotherapy of cancer

• How cellular pathways of protein processing and pivotal cell-death pathways are being targeted by new Therapies New therapeutic targets in epigenetic and newly described metabolic pathways that serve as new pathways for drug discovery

• Advances in targeting angiogenesis

• Important new animal models for target validation

• New approaches to drug-conjugates and to dose evaluation for effective therapy

Preliminary Sessions for 2013 Agenda:

• Novel Kinase Inhibitors & Beyond the Kinome

• Functional Genomics & Future Cancer targets

• Novel Antibody-based Modalities

• Progress in Cancer Immunotherapy

• Cancer Stem Cells, Metabolism, Cancer Epigenetics

• Novel Advances & Technologies in Oncology

This conference is part of our 2nd Novel Cancer Therapeutics Summit which consists of two other concurrent conferences shown below:

2nd Novel Cancer Therapeutics Summit:

• Track: 4th Cancer Targets & Therapeutics

• Track: 2nd Oncology Partnering & Deal-making

• Track: 3rd Ubiquitin Research & Drug Discovery